Loading…
AnaptysBio, Inc. is projected to rise to $96.18 by 2027, a +45% move from its current price of $66.39. ANAB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $64.51 | $66.39 | $68.33 | 0.00% |
| Jul 14 | $63.74 | $66.39 | $69.15 | 0.00% |
| Jul 15 | $63.16 | $66.39 | $69.79 | 0.00% |
| Jul 16 | $62.68 | $66.39 | $70.33 | 0.00% |
| Jul 17 | $62.25 | $66.39 | $70.81 | 0.00% |
| Jul 18 | $61.87 | $66.39 | $71.25 | 0.00% |
| Jul 19 | $61.52 | $66.39 | $71.65 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $61.52 | $66.39 | $71.65 | +0.01% |
| Week 2 | $59.61 | $66.40 | $73.95 | +0.01% |
| Week 3 | $58.19 | $66.40 | $75.77 | +0.02% |
| Week 4 | $57.02 | $66.41 | $77.34 | +0.02% |
| Week 5 | $56.01 | $66.41 | $78.75 | +0.03% |
| Week 6 | $55.11 | $66.41 | $80.04 | +0.03% |
| Week 7 | $54.29 | $66.42 | $81.25 | +0.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. It is based in San Diego, California.
Its product portfolio includes Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc.
and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
AnaptysBio, Inc. (ANAB) is a healthcare stock with a current price of $63.15 and a market capitalization of $1.84B. It is ranked 2099 by market cap among equities.
The price outlook reflected in the forecast sequence shows upside from 2026 through 2050, with the 2026 average price at $63.15 and the trajectory rising to a 2030 average of $139.03 and a 2050 average of $1,013.04. The forecast also indicates bullish sentiment for most of the horizon beyond 2026.
A major floor 46.9% below — a decisive break under it would weaken the trend.
The nearest floor, 24.1% below — buyers have tended to step in here.
Price is pressing into resistance (1.7% away) — a breakout level to watch.
A major ceiling 18.3% above — clearing it would confirm fresh momentum.
Key ANAB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ANAB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $65.59 | Buy | $65.80 | Buy |
| MA 10 | $65.34 | Buy | $64.59 | Buy |
| MA 20 | $61.64 | Buy | $62.42 | Buy |
| MA 50 | $60.63 | Buy | $58.57 | Buy |
| MA 100 | $51.79 | Buy | $52.40 | Buy |
| MA 200 | $39.50 | Buy | $42.89 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.16 | Neutral |
| Stoch RSI (14) | 39.33 | Neutral |
| CCI (20) | 85.49 | Neutral |
| Williams %R (14) | -12.31 | Info |
| MACD (12,26,9) | 0.49 | Buy |
| ROC (12) | 11.71 | Buy |
| Bollinger %B (20,2) | 0.79 | Neutral |
| Stochastic %K (14) | 87.69 | Sell |
| TRIX (15) | 0.48 | Buy |
| Awesome (5,34) | 6.95 | Buy |
| Ultimate (7,14,28) | 54.12 | Neutral |
| Momentum (10) | 6.71 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 66.55 | Sell |
| ADX (14) | 21.33 | Buy |
| ATR (14) | 1.72 | Info |
The 30-day technical picture is bullish, with RSI(14) at 60. The stock trades above the SMA50 of $58.60 and well above the SMA200 of $37.19, indicating upside momentum.
Near-term support sits at $50.37 and resistance at $63.15. The 30-day range runs from a low of $52.46 to a high of $76.01, suggesting substantial near-term volatility within a constructive framework.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $28.80 | $66.39 | $89.68 | 0% | Neutral | |
| $76.19 | $96.18 | $128.70 | +45% | Bullish | |
| $85.10 | $110.66 | $153.92 | +67% | Bullish | |
| $87.38 | $116.45 | $166.94 | +75% | Bullish | |
| $105.35 | $143.49 | $210.99 | +116% | Bullish | |
| $116.04 | $161.22 | $242.37 | +143% | Bullish | |
| $136.13 | $192.66 | $295.43 | +190% | Bullish | |
| $174.80 | $251.71 | $392.99 | +279% | Bullish | |
| $190.01 | $278.16 | $441.52 | +319% | Bullish | |
| $209.22 | $311.17 | $501.52 | +369% | Bullish | |
| $340.98 | $544.97 | $936.49 | +721% | Bullish | |
| $577.63 | $1,045.81 | $1,972.53 | +14.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $28.80 | $66.39 | $79.68 | +0.00% |
| August 2026 | $55.38 | $65.45 | $79.51 | -1.41% |
| September 2026 | $55.80 | $66.44 | $81.66 | +1.51% |
| October 2026 | $57.95 | $69.44 | $86.19 | +4.52% |
| November 2026 | $58.32 | $70.26 | $87.93 | +1.18% |
| December 2026 | $58.73 | $71.12 | $89.68 | +1.22% |
Click any year to see its month-by-month ANAB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ANAB price prediction for 2026 points to an average of $66.39 (low $28.80, high $89.68) — a potential gain of 0% on today's $66.39. A consolidation phase looks the most probable path here.
In 2027, ANAB is projected to trade between $76.19 and $128.70, averaging $96.18 — a potential gain of +45% from today's $66.39. That is up +45% on the projected 2026 average. Momentum favours further upside here.
AnaptysBio, Inc.'s 2028 outlook centres on $110.66, within a $85.10 to $153.92 range. That is up +15% on the projected 2027 average. That marks a +67% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ANAB could reach as high as $166.94, with a base case around $116.45 and support toward $87.38 — roughly +75% from $66.39. Momentum favours further upside here.
Expect ANAB to range from $105.35 to $210.99 through 2030. The $143.49 average target implies a +116% move from current prices. That is up +23% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ANAB price prediction for 2031 points to an average of $161.22 (low $116.04, high $242.37) — a potential gain of +143% on today's $66.39. Momentum favours further upside here.
In 2032, ANAB is projected to trade between $136.13 and $295.43, averaging $192.66 — a potential gain of +190% from today's $66.39. That is up +19% on the projected 2031 average. Buyers look set to stay in control over this stretch.
AnaptysBio, Inc.'s 2033 outlook centres on $251.71, within a $174.80 to $392.99 range. That is up +31% on the projected 2032 average. That marks a +279% change versus current levels. Momentum favours further upside here.
By 2034, ANAB could reach as high as $441.52, with a base case around $278.16 and support toward $190.01 — roughly +319% from $66.39. Buyers look set to stay in control over this stretch.
Expect ANAB to range from $209.22 to $501.52 through 2035. The $311.17 average target implies a +369% move from current prices. That is up +12% on the projected 2034 average. Momentum favours further upside here.
The ANAB price prediction for 2040 points to an average of $544.97 (low $340.98, high $936.49) — a potential gain of +721% on today's $66.39. Buyers look set to stay in control over this stretch.
In 2050, ANAB is projected to trade between $577.63 and $1,972.53, averaging $1,045.81 — a potential gain of +14.8x from today's $66.39. That is up +92% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ANAB today (≈ 15.062509 ANAB) could be worth
$15,752.57
+$14,752.57 (+1475%) by 2050 · US Dollar
Based on the average projected ANAB price of $1,045.81 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ANABwould be worth at today's price.
$1,000 invested in ANAB on Jul 10, 2025 (≈ 57.493292 ANAB) would be worth
$3,816.98
+$2,816.98 (+281.7%) today · 3.82× · US Dollar
Based on a ANAB entry price of $17.39 vs. today's $66.39.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $63.42 | $1,046.83 | +4.7% |
| 1 month ago | $52.1 | $1,274.28 | +27.4% |
| 3 months ago | $46.73 | $1,420.61 | +42.1% |
| 6 months ago | $32.69 | $2,031.1 | +103.1% |
| 1 year ago | $17.39 | $3,816.98 | +281.7% |
| All time (5.0y) ago | $17.33 | $3,830.19 | +283.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ANAB forecast.
Our base-case forecast reaches $130.00 around 2030.
Implied market cap at $130.00: $3.85B
The multi-year forecast shows meaningful upside across the horizon. In 2026 the min is $28.80, the avg is $63.15, and the max is $87.61, with a neutral tone. By 2027 the avg rises to $92.62 and the max to $123.77 with a bullish sentiment, followed by 2028 avg $104.28 and max $144.68, and 2029 avg $112.30 with a max of $160.44.
The outlook strengthens further into 2030 with an avg of $139.03 and a max of $203.61, delivering a 120.2% ROI. By 2031 the avg is $152.73 (max $228.57) and by 2032 the avg is $184.61 (max $281.70), continuing the bullish trend through 2033 ($242.05 avg, $375.89 max) and 2034 ($262.94 avg, $415.00 max). The path remains bullish into 2035 ($297.63 avg, $476.84 max) and into 2040, where the avg is $506.83 and the max $864.72, a 702.6% ROI.
By 2050 the forecast shows an avg of $1,013.04 and a max of $1,894.13, representing a 1504.2% ROI.
These are estimates, not guarantees, and reflect market-implied scenarios with bullish sentiment across much of the forecast horizon. Investors should consider that outcomes depend on numerous uncertain factors and that outcomes may differ from the projected paths.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $139.03 with a min of $102.43 and a max of $203.61, and an ROI of 120.2%, with a bullish sentiment.
Forecasts indicate bullish sentiment from 2027 onward, with rising averages through 2030 and beyond (e.g., 2030 avg $139.03; 2040 avg $506.83; 2050 avg $1,013.04). However, the 2026 outlook is neutral and these are estimates, not guarantees.
Yes. The 2030 maximum is $203.61, which crosses the $200 level, with an average of $139.03 and a range from $102.43 to $203.61.
The current price is $63.15. The 30-day range is a low of $52.46 and a high of $76.01.
Market cap is $1.84B and the stock is ranked 2099.
AnaptysBio, Inc. Community Discussion
0Share your AnaptysBio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.